Noopept

Noopept (GVS-111, omberacetam) is a synthetic small molecule designed as a piracetam analog with 1,000-fold higher potency and oral bioavailability. Developed at the V.V. Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences by Tatiana Gudasheva and colleagues, it was first synthesized in 1996 and has been approved as a prescription nootropic in Russia since the late 1990s. The compound is a prodrug of cycloprolylglycine (CPG), an endogenous neuropeptide. Mechanism centers on hippocampal BDNF and NGF upregulation, AMPA receptor modulation through CPG, and cholinergic enhancement. The Russian clinical-trial base is meaningful but Western independent replication is limited. Noopept has no FDA drug approval and is sold as a research chemical in most non-CIS markets.

Development and Origin

The compound was designed at the Zakusov Institute of Pharmacology in Moscow in the early 1990s. The design rationale: piracetam (the prototype nootropic, developed by UCB Pharma in Belgium in 1964) had a favorable safety profile and modest cognitive-enhancing activity but required gram-scale doses. The Gudasheva group sought to design a more potent analog that retained piracetam's mechanism while reducing the dose requirement.

The structural approach was to extend the piracetam pyrrolidinone scaffold with a phenylacetyl group and to terminate the molecule as an ethyl ester. The result was N-phenylacetyl-L-prolylglycine ethyl ester, designated GVS-111 during development and patented in 1995 (US Patent 5,439,930) and 1996 (Russian Patent 2119496). The compound was marketed as Noopept by JSC LEKKO Pharmaceuticals after Russian regulatory approval.

The compound has the International Nonproprietary Name (INN) omberacetam, although this name is rarely used in nootropic community contexts where "Noopept" dominates.

The Cycloprolylglycine Metabolite

A key biochemical observation came from Gudasheva et al. 1997, which characterized the brain metabolism of Noopept and identified the principal active metabolite as cycloprolylglycine (CPG, cyclo-L-prolylglycine). This is an endogenous neuropeptide present in human brain tissue, and it is also a known metabolite of insulin-like growth factor 1 (IGF-1).

The pharmacokinetic implication: Noopept itself has a short half-life of approximately 5 to 10 minutes in rodents and is not detectable in brain tissue one hour after dosing. The behavioral effects, however, persist for hours, because CPG accumulates in brain tissue and persists longer than the parent compound. CPG is the molecule that does most of the work.

CPG is sufficiently interesting on its own that it has been pursued as a separate therapeutic development program. Neuren Pharmaceuticals has been developing CPG-derived compounds for rare neurological diseases, including trofinetide (which is now FDA-approved for Rett syndrome).

Mechanism Evidence

Ostrovskaya et al. 2008 characterized the BDNF and NGF effects in detail in rat models:

• Acute single-dose administration: hippocampal BDNF mRNA increased approximately 1.4-fold within 3 hours. Hippocampal NGF mRNA increased approximately 1.5-fold. Cerebral cortex showed slight decreases in both factors acutely.
• Chronic administration (28 days): hippocampal BDNF and NGF expression continued to rise without tolerance. Cortical BDNF began increasing after the initial acute suppression.

The non-tolerance pattern with continued administration is unusual. Most receptor-activating compounds produce some compensatory downregulation. The Ostrovskaya group interpreted the result as a sustained neurotrophic enhancement rather than acute receptor stimulation.

Ostrovskaya et al. 2014 extended the mechanism to Alzheimer's-relevant cellular models, showing that Noopept reduced apoptosis and tau hyperphosphorylation in beta-amyloid-treated cell cultures. The proposed pathway involves Bcl-2 family upregulation, caspase inhibition, and reduced GSK-3β-mediated tau phosphorylation.

AMPA Receptor Modulation

CPG, the active metabolite, is a positive allosteric modulator of AMPA-type glutamate receptors. AMPA receptors mediate fast excitatory synaptic transmission and are central to long-term potentiation (LTP), the cellular substrate of memory formation. Low-dose AMPA receptor sensitization without overt agonism is a desirable nootropic profile, since direct agonists cause excitotoxicity at high doses.

The AMPA modulation is dose-related: too-low doses do not reach the threshold, too-high doses can over-stimulate and cause irritability or anxiety. This dose-window characteristic is consistent with reports from off-label users that 10 to 20 mg typically produces favorable effects while 30 to 60 mg can produce paradoxical anxiety or irritability.

Russian Clinical Trial Base

The clinical evidence supporting Noopept's Russian approval consists of trials in:

• Cognitive impairment of various etiologies (vascular, post-traumatic, post-stroke, mild Alzheimer's)
• Asthenia (chronic fatigue) following infectious or somatic illness
• Post-stroke cognitive recovery

Trial designs are heterogeneous, sample sizes are typically small (50 to 200 patients), and most published reports are in Russian-language journals with limited access. The Western academic literature on Noopept is small. The AlzForum Cognitive Vitality report lists 0 observational studies in the Western academic database.

Western Clinical Validation

Independent Western clinical trials are essentially absent. Noopept has not been pursued by any major pharmaceutical company outside Russia. The compound is patent-protected (in the original patent senses) but the pharmaceutical commercial calculus has not favored Western development. The structural simplicity, oral bioavailability, and well-characterized rodent mechanism would in principle support Western development, but the regulatory and commercial path has not been undertaken.

Regulatory Status by Jurisdiction

• Russia and CIS states: prescription nootropic, approved indications include cognitive impairment, post-stroke recovery
• United States: not FDA-approved as drug. Sold as research chemical or dietary supplement under structure-function framing. Legal status of supplement marketing is contested
• European Union: not approved. Sold as research chemical
• United Kingdom: covered by the Psychoactive Substances Act 2016, which restricts commercial sale. Personal possession is not criminalized
• Australia: similar restrictions to UK
• Canada: not approved

Noopept's mechanism operates through its active metabolite cycloprolylglycine (CPG) acting on multiple central nervous system targets. The major characterized pathways:

Prodrug Conversion

Noopept is rapidly absorbed orally with peak plasma concentrations within 15 to 60 minutes. Plasma half-life of the parent compound is approximately 5 to 10 minutes in rodents (human pharmacokinetics is less well-characterized but appears similar by extrapolation). The phenylacetyl group is hydrolyzed by plasma esterases, and the ethyl ester is hydrolyzed by ubiquitous esterases, producing L-prolylglycine which cyclizes spontaneously to form cycloprolylglycine (CPG).

CPG crosses the blood-brain barrier readily because of its small size and balanced polarity. Brain concentrations of CPG peak approximately 1 to 2 hours after oral Noopept dosing and persist for several hours.

BDNF and NGF Upregulation

The principal proposed nootropic mechanism is upregulation of hippocampal brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Both are neurotrophins that support neuronal survival, synapse formation, and synaptic plasticity. The Ostrovskaya 2008 paper documented:

• Acute single-dose: hippocampal BDNF +1.4×, hippocampal NGF +1.5×, at 3 hours post-dose
• 28-day chronic: hippocampal BDNF and NGF continue rising, no tolerance
• Cortical effects: initial acute suppression, then gradual increase with chronic dosing

BDNF activation triggers TrkB receptor signaling, which propagates downstream through PI3K/AKT (survival), MAPK/ERK (plasticity-related gene expression), and PLCγ (calcium signaling) pathways.

AMPA Receptor Modulation

CPG functions as a positive allosteric modulator at AMPA-type glutamate receptors. The effect is dose-dependent and modest, consistent with the nootropic profile (enhancement without excitotoxicity).

Cholinergic Enhancement

Noopept has been characterized as cholinergic-enhancing, with effects on acetylcholine release in hippocampus and frontal cortex. The molecular basis is less well characterized than the BDNF mechanism but contributes to the cognitive-enhancing profile.

Anti-Apoptotic and Neuroprotective Effects

The Ostrovskaya 2014 paper documented:

• Bcl-2 family upregulation: reduced pro-apoptotic Bax, increased anti-apoptotic Bcl-2
• Caspase inhibition: reduced caspase-3 activation
• Tau hyperphosphorylation reduction: GSK-3β inhibition, reducing pathological tau phosphorylation relevant to Alzheimer's disease

Anti-Inflammatory and Antioxidant Effects

Older Russian literature describes anti-inflammatory and antioxidant effects, including reduced lipid peroxidation, reduced microglial activation, and modulation of pro-inflammatory cytokines. The mechanistic detail in these reports is less developed than the BDNF and AMPA pathway evidence.

Acute effects (single dose, hours):

• Mild improvement in attention and focus
• Subjective mental clarity (commonly reported in nootropic communities)
• Mild anxiolytic effect in some users
• Reaction-time improvements in some laboratory tasks
• Anxiogenic and irritability effects in a subset of users (dose-related)

Chronic effects (weeks):

• Memory improvement in cognitive impairment populations (Russian clinical trials)
• Cognitive recovery after stroke in Russian protocols
• Improved performance on memory and learning tasks in rodent models
• Reduced apathy and improved mood in some patient populations

Effects in rodent models (broader evidence base than human trials):

• Improved Morris water maze performance
• Reversed scopolamine-induced amnesia
• Improved passive avoidance learning
• Reduced cognitive deficit in Alzheimer-relevant models
• Reduced stroke damage in middle cerebral artery occlusion models
• Increased BDNF, NGF, and synaptophysin expression
• Reduced amyloid-induced neuronal death in cell culture
• Reduced tau hyperphosphorylation

Subjective user reports from nootropic and biohacker communities:

• Mental clarity and focus, particularly for verbal tasks
• Improved mood at low doses (10 to 20 mg)
• Anxiety or irritability at higher doses (30 to 60 mg)
• Variable response: some users describe Noopept as among the most useful nootropics they have tried, others describe it as ineffective or as paradoxically anxiogenic
• Reports of vivid dreams or sleep architecture changes in some users
• Tolerance does not appear to develop with continued use in subjective reports, consistent with the rodent pharmacology

Honest evidence framing: Noopept has a meaningful Russian clinical-trial base but limited Western independent replication. The mechanistic story (BDNF/NGF, AMPA modulation, CPG metabolite) is biologically plausible and supported by preclinical evidence. The translation to large-scale, rigorously controlled cognitive enhancement in healthy adults has not been demonstrated. The response heterogeneity (some users respond strongly, others not at all) suggests that individual factors may matter substantially.

Russian clinical protocols:

• Standard adult dose: 10 mg orally three times daily (30 mg total daily), tablets
• Starting dose: 10 mg twice daily for the first week, then titrate to three times daily
• Treatment duration: typically 8 to 12 weeks for cognitive impairment indications
• Post-stroke recovery: similar 30 mg/day for 8 to 12 weeks
• Cycle: no formal cycling protocol. Some clinicians suggest break periods after extended treatment, but the rodent data shows no tolerance development at 28 days

Off-label community protocols:

• Acute use: 10 to 20 mg as a single dose, taken sublingually or orally before cognitive tasks
• Daily use: 10 to 30 mg per day, split into 2 to 3 doses
• Cycling: many users cycle 4 to 12 weeks on, 1 to 4 weeks off, though there is no controlled evidence to support specific cycling schedules
• Stacking with choline: many users co-supplement with alpha-GPC or CDP-choline (citicoline) at 300 to 600 mg per day, on the rationale that cholinergic enhancement is part of Noopept's mechanism

Bioavailability and timing:

• Oral bioavailability: adequate (specific percentage not well characterized in humans)
• Sublingual: faster onset, similar total exposure
• Effect onset: 15 to 60 minutes
• Effect duration: 4 to 8 hours subjectively, despite the short parent half-life, because CPG persists in brain tissue
• Steady state with chronic dosing: reached within several days

Special populations:

• Older adults: standard dosing. The cognitive impairment indications in Russia are primarily in this population
• Pregnancy and breastfeeding: not studied. Avoid
• Pediatric: not approved or studied. Avoid
• Renal/hepatic impairment: limited data. Standard dose reduction principles apply

Stability and storage: room temperature, dry, protected from light. Noopept is stable as a solid powder or tablet. Sublingual tablets and powder formulations are both common.

Common adverse effects (Russian trial data, 30 mg/day for 8 to 12 weeks):

• Irritability and emotional lability
• Insomnia (particularly with late-day dosing)
• Headache
• Mild dizziness
• Anxiety in a subset of users
• Mild gastrointestinal complaints (nausea, occasional)
• Fatigue (paradoxical, in some users)

Less common adverse effects:

• Allergic reactions (skin rash, rare)
• Blood pressure fluctuations (occasionally reported)
• Mild appetite changes
• Dry mouth

Specific patterns reported in nootropic communities:

• Paradoxical anxiety at doses >30 mg/day. Reducing dose typically resolves
• Brain fog or cognitive worsening in a minority of users, mechanism unexplained
• Mood swings in users who are sensitive to glutamate-modulating compounds
• Sleep disturbance if dosed within 6 hours of bedtime

Pharmacological safety profile (rodent):

• LD50 in rats: very high. Oral toxicity is not a practical concern at therapeutic doses
• No mutagenicity in Ames test
• No teratogenicity in standard rodent reproductive studies (though human pregnancy data is absent)
• No tolerance development at 28 days
• No discontinuation syndrome characterized

Drug interaction considerations:

• Stimulants (caffeine, amphetamines, modafinil): additive anxiogenic effects in some users
• Other glutamatergic compounds (high-dose racetams, ampakines): theoretical additive effects on AMPA signaling
• Anticholinergics: may reduce nootropic efficacy
• MAO inhibitors: not characterized
• Antidepressants (SSRI/SNRI): not formally characterized. Anecdotal reports of additive serotonergic effects in some users
• Alcohol: anecdotal reports of reduced subjective alcohol intoxication, mechanistic basis unclear

Long-term safety: not well characterized beyond 12 weeks in clinical trials. Russian patients with prescription use for chronic cognitive impairment may use Noopept for longer durations but systematic long-term safety data is absent.

Pregnancy and breastfeeding: avoid. No human safety data.

Pediatric use: not approved or studied. Avoid in patients under 18.

Noopept sits in the cognitive-enhancing nootropic category alongside the racetams and other peptide-derived cognitive compounds. Its closest comparators:

• Piracetam: the prototype racetam. Approximately 1,000-fold less potent than Noopept, requires gram-scale dosing. Approved as a prescription nootropic in many European countries and the original "smart drug." Mechanism overlaps with Noopept (AMPA, cholinergic) but lacks the BDNF/NGF effect.
• Phenylpiracetam: a more potent racetam variant with an additional phenyl group. Slightly stimulant-like profile, approved in Russia, banned by WADA for athletes. Different profile from Noopept.
• Aniracetam, Oxiracetam, Pramiracetam: other racetam family members with various potency and subjective profiles. None match Noopept's BDNF/NGF effect specifically.
• Semax: Russian ACTH(4-10)-derived peptide nootropic with cholinergic and BDNF effects. Intranasal route, different pharmacokinetics, similar Russian regulatory and research-chemical context globally.
• Selank: Russian tuftsin-derived peptide with anxiolytic and mild nootropic effects. Intranasal route. Complementary to Noopept in some stacking protocols.
• Cerebrolysin: porcine-brain-derived peptide preparation with BDNF-like effects. Injectable. More clinical evidence base than Noopept, particularly in stroke and dementia.
• Dihexa: angiotensin-IV-derived peptidomimetic with HGF/c-Met mechanism. Different mechanism, less clinical history, more aggressive marketing claims.
• Lion's Mane (Hericium erinaceus): medicinal mushroom with NGF-inducing effects. Different chemistry, different evidence base, often used as a natural-product alternative or adjunct.

Common stacks circulating in nootropic communities:

• Noopept + Alpha-GPC or CDP-choline: the most common stack. Choline precursor co-supplementation addresses the cholinergic enhancement aspect of Noopept's mechanism and is reported by users to reduce headaches and improve subjective effects. Typical doses: 300 to 600 mg alpha-GPC or 250 to 500 mg CDP-choline per day.
• Noopept + Lion's Mane: combined neurotrophic factor stack. NGF from Lion's Mane, BDNF/NGF from Noopept. Plausible additivity, no controlled evidence.
• Noopept + Semax: combined cognitive enhancement and BDNF effects. No controlled trials.
• Noopept + Selank: combined cognitive enhancement and anxiolytic effects, often used by users who experience anxiety with Noopept alone.
• Noopept + Caffeine + L-theanine: classic "focus stack" combination. Caffeine and L-theanine separately and the Noopept addition for memory consolidation. No controlled evidence but widely reported.
• Noopept + Modafinil: combined wakefulness and cognitive enhancement. Anxiogenic risk in sensitive users.

Combinations to avoid or use with caution:

• High-dose stimulants: additive anxiety risk
• Pregnancy or breastfeeding: avoid all nootropic compounds without medical supervision
• History of anxiety disorders: start at low doses (10 mg) and titrate carefully
• History of psychotic disorders: not characterized. Theoretical concern with glutamatergic modulation
• Active SSRI or SNRI use: not well characterized. Some users report anxiogenic interactions

The most actionable framing of Noopept in 2026: this is one of the most-used research-chemical nootropics, with a 30-year history of prescription use in Russia and an extensive online user base. The Russian clinical-trial base supports cognitive impairment and post-stroke recovery indications at 30 mg/day for 8 to 12 weeks. Western independent replication is limited and the compound has no FDA approval. The mechanism (BDNF/NGF via cycloprolylglycine) is biologically plausible and supported by preclinical evidence. Response heterogeneity is real: some users benefit, others experience paradoxical anxiety or no effect.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.